

contents

Terminology	vi
CONCLUSIONS AND RECOMMENDATIONS	1
Charge to the Panel	5
Scope of the Study	7
DISCUSSION OF CONCLUSIONS AND RECOMMENDATIONS	9
1 Variations in Bioavailability Of Drug Products	11
2 Variations in Bioavailability And Therapeutic Failure	13
3 Analytical Methodology For Bioavailability Studies	15
4 Drug Classes Requiring Bioavailability Studies	21
5 Present Standards And Manufacturing Practice Guidelines	25
6 New Standards And Manufacturing Practice Guidelines	35
7 Need for Additional Research	43
8 Use of Manufacturing Records And Information	47
9 Repeal of Exemptions in Current Law	51
10 New Standard-Setting Organization	53
11 List of Interchangeable Drug Products	57
Bibliography	61
Appendix	71
Glossary	75

terminology

Definitions of key technical terms as we have used them in this report are presented below. A comprehensive glossary of these and other technical terms is also provided on page 75.

- Drug product A dosage form containing one or more active therapeutic ingredients along with other substances included during the manufacturing process.
- Present compendia standards The official standards for drug excipients and drug products listed in the latest revision of the United States Pharmacopoeia (USP) and the National Formulary (NF).
- New compendial standards Standards to be established for active ingredients, excipients and drug products, including tests selecting the best available technology to be performed before, during and after formulation.
- Chemical equivalents Drug products that contain the same amounts of the same therapeutically active ingredients in the same dosage forms and that meet present compendia standards.
- Pharmaceutical equivalents Drug products that contain the same amounts of the same therapeutically active ingredients in the same dosage form and that meet standards to be established on the basis of the best available technology.
- Bioavailability The extent and rate of absorption from a dosage form as reflected by the time-concentration curve of the administered drug in the systemic circulation.
- Bioequivalents Chemical equivalents which, when administered to the same individuals in the same dosage regimen, will result in comparable bioavailability.
- Therapeutic equivalents Chemical equivalents which, when administered to the same individuals in the same dosage regimen, will provide essentially the same efficacy and/or toxicity.
- Interchangeable drug products Pharmaceutical equivalents or bioequivalents that are accepted as therapeutic equivalents.